2025
SJR Q1
JCR Q1 · 8,2
3 matched articles
SCIE
Journal detail
European Heart Journal - Cardiovascular Pharmacotherapy
- Publisher
- Oxford University Press
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
2055683720556845
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 2,014
- Quartile Q1
- H-Index 50
- Cites/doc 4,32
- Docs (3y) 308
- Cites (3y) 1.311
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 8,2
- 5Y JIF 6,1
- JCI 1,43
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 2,014 | 8,2 | 6,1 | 1,43 | Q1 | 50 |
| 2024 | Q1 | Q1 | 2,043 | 6,1 | 5,6 | 1,61 | Q1 | 45 |
| 2023 | Q1 | Q1 | 1,507 | 5,4 | 5,1 | 1,69 | Q1 | 45 |
| 2022 | Q1 | Q1 | 1,641 | 7,1 | 6,6 | 1,71 | Q1 | 45 |
| 2021 | Q1 | Q1 | 1,662 | 11,2 | 8,2 | 1,57 | Q1 | 45 |
| 2020 | Q1 | Q1 | 1,895 | 6,6 | 5,8 | 1,52 | Q1 | 45 |
| 2019 | Q1 | Q1 | 1,725 | 6,7 | — | 1,53 | Q1 | 45 |
| 2018 | — | Q1 | — | 6,7 | — | 1,5 | Q1 | — |
| 2017 | — | — | — | — | — | — | — | 45 |
| 2016 | — | — | — | — | — | — | — | 45 |
| 2015 | — | — | — | — | — | — | — | 45 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 28/237 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 20/356 |
| 2024 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 30/231 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 31/352 |
| 2023 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 36/222 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 32/354 |
| 2022 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 25/143 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 26/278 |
| 2021 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 15/143 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 14/279 |
| 2020 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 22/142 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 23/276 |
| 2019 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 16/138 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 15/271 |
| 2018 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | Q1 | 13/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 13/267 |